Recurrent Adult Immunoblastic Large Cell Lymphoma Completed Phase 2 Trials for Cyclophosphamide (DB00531)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01093586Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment
NCT01427881Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesTreatment
NCT00049504Fludarabine Phosphate, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Total-Body Irradiation, and Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerTreatment
NCT00073918Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTreatment
NCT01177371High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaTreatment